4//SEC Filing
Sullivan Mark 4
Accession 0001485003-23-000111
CIK 0001485003other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 8:46 PM ET
Size
12.8 KB
Accession
0001485003-23-000111
Insider Transaction Report
Form 4
Sesen Bio, Inc.SESN
Sullivan Mark
General Counsel & Secretary
Transactions
- Sale
Common Stock
2023-03-02$0.59/sh−73,361$43,063→ 310,355 total - Sale
Common Stock
2023-03-02$0.59/sh−44,879$26,344→ 378,651 total - Sale
Common Stock
2023-03-02$0.59/sh−100,978$59,274→ 198,716 total - Exercise/Conversion
Common Stock
2023-03-02$0.59/sh+185,000$108,595→ 383,716 total - Exercise/Conversion
Common Stock
2023-03-02$0.59/sh+113,175$66,434→ 423,530 total
Footnotes (6)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above.
- [F3]Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
- [F4]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 21, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F5]Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
- [F6]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Documents
Issuer
Sesen Bio, Inc.
CIK 0001485003
Entity typeother
Related Parties
1- filerCIK 0001331843
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 8:46 PM ET
- Size
- 12.8 KB